Decreased Accessibility and Lack of Activation of ErbB2 in JIMT-1, a Herceptin-Resistant, MUC4-Expressing Breast Cancer Cell Line
2005 · Cancer Research · 510 citations
https://doi.org/10.1158/0008-5472.473.65.2
A
Anita I. Kapanen
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
55
Papers
2.8K
Citations
17
h-index
20
i10-index
Anita I. Kapanen is an academic researcher from University of British Columbia. The author has contributed to research in topics: Pharmaceutical Practices and Patient Outcomes & HER2/EGFR in Cancer Research & Monoclonal and Polyclonal Antibodies Research. The author has an h-index of 17, co-authored 47 publications.
ORCID: 0000-0001-6091-9818Papers by this author
worksCharacterization of a novel cell line established from a patient with Herceptin-resistant breast cancer
2004 · Molecular Cancer Therapeutics · 268 citations
https://doi.org/10.1158/1535-7163.1585.3.12
Trastuzumab causes antibody-dependent cellular cytotoxicity–mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance
2007 · Molecular Cancer Therapeutics · 236 citations
https://doi.org/10.1158/1535-7163.mct-06-0766
Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs
2007 · Molecular Cancer Therapeutics · 59 citations
https://doi.org/10.1158/1535-7163.mct-06-0159
The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity
2011 · BMC Cancer · 28 citations
https://doi.org/10.1186/1471-2407-11-420
Unpacking the value of pharmacists in team-based primary care in British Columbia, Canada: a qualitative evaluation
2025 · BMC Primary Care · 0 citations
https://doi.org/10.1186/s12875-025-03131-2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat